Dementia Matters23 Jan 2024

Looking at Lecanemab’s Eligibility Guidelines and Prescription Process

In the past few years, new therapies shown to slow the progression of Alzheimer's disease in people in the early stages of the disease have been making their way through the U.S. Food and Drug Administration’s (FDA) approval process. With these treatments now available, there are a growing number of questions surrounding who is eligible to take these medications and what processes are needed to ensure they are prescribed safely and effectively. Host Dr. Nathaniel Chin examines the guidelines for geriatricians and clinicians prescribing lecanemab and breaks down the eligibility requirements necessary to receive this treatment.

Show Notes

Read Eisai/Biogen’s “Prescribing Information” for Leqembi online.

Read “Lecanemab: Appropriate Use Recommendations” on the National Library of Medicine website.

Read the U.S. Department of Veterans Affairs’ (VA) guidelines for prescribing lecanemab, “Lecanemab-irmb (LEQEMBI) Criteria for Use August 2023,'' online.

Listen to previous Dementia Matters episodes on lecanemab, including “Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment,” “A Closer Look at the Lecanemab Clinical Trials,” and “Introducing Lecanemab, The Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval,” on our website and all major podcast platforms.

Connect with Us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(244)

New Alzheimer’s Association Special Report Breaks Down How Americans Understand and Support their Brain Health

In recent years, public interest in brain health has increased. So how are Americans understanding brain health information and incorporating it into their own lives? This year, the Alzheimer’s Associ...

25 Aug 37min

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Twenty-five years ago, a single participant enrolled in what would become the Wisconsin Registry for Alzheimer's Prevention (WRAP), now one of the largest and longest-running studies of Alzheimer's ri...

12 Aug 35min

How Dementia Caregiving Affects the Spousal Caregiver

Caring for those with dementia represents a major public health challenge, with caregivers, especially spouses, providing long-term, largely unpaid care. With caregiving stress linked to a decline in ...

28 Jul 39min

Managing the Medicine Cabinet: How Prescriptions Impact Cognition and Brain Health as We Age

Prescription medications, over-the-counter drugs and supplements are incredibly common among older adults, yet many of these routine treatments can unexpectedly impact cognitive function and brain hea...

14 Jul 35min

Taking a Deep Dive into Subjective Cognitive Decline

Dr. Jessen returns to the podcast to take a deeper dive into subjective cognitive decline (SCD). Aiming to cover everything relating to SCD, Dr. Jessen shares insights in prognosis, risk factors and h...

7 Jul 17min

Defining Subjective Cognitive Decline

Subjective cognitive decline (SCD) can be one of the earliest noticeable signs of Alzheimer's disease, yet SCD is not yet fully understood. To help us understand more, Dr. Frank Jessen, an expert in t...

30 Jun 30min

SPRINT to a Healthy Mind: How Blood Pressure Control Affects Brain Health and Dementia Risk

Geriatrician Dr. Mark Supiano joins the podcast to discuss the connection between heart and brain health. Citing multiple clinical trials, he breaks down what these studies and their findings mean for...

18 Jun 40min

Addressing Cochrane’s Review on Amyloid-Targeting Treatments for Alzheimer’s Disease

Amyloid-targeting monoclonal antibody treatments have ushered in a new era of Alzheimer’s disease therapies after decades of research and clinical trials. A recent review published by Cochrane, a glob...

4 Jun 44min